Automated liquid handling extraction and rapid quantification of underivatized amino acids and tryptophan metabolites from human serum and plasma using dual-column U(H)PLC-MRM-MS and its application to prostate cancer study

Abstract

AbstractFree amino acids (AAs) and their metabolites are important building blocks, energy sources and signaling molecules associated with various pathological phenotypes. The quantification of AA and tryptophan (TRP) metabolites in human serum and plasma is therefore of great diagnostic interest. Robust and reproducible sample extraction and processing workflows as well as rapid, sensitive absolute quantification of AA and TRP metabolites are required to identify candidate biomarkers and to improve current screening methods. We developed a validated semi-automated extraction and sample processing workflow using a robotic liquid handling platform and a rapid method for the absolute quantification of 20 free, underivatized AAs and 6 TRP metabolites using dual-column U(H)PLC-MRM-MS. The automated extraction and sample preparation workflow is designed for use in a 96-well plate format, allowing robust and reproducible high sample throughput without the need for further SPE, evaporation and/or buffer exchange. Samples extracted from serum and/or plasma in 96-well plates can be transferred directly to the U(H)PLC autosampler. The dual-column U(H)PLC-MRM-MS method, using a mixed- mode reversed-phase anion exchange column with formic acid as mobile phase modifier and a high- strength silica reversed-phase column with difluoroacetic acid as mobile phase additive, provided absolute quantification with nanomolar lower limits of quantification (LLOQ) for all metabolites except glycine (LLOQ: 2.46 µM) in only 7.9 minutes. The semi-automated extraction workflow and dual-column U(H)PLC-MRM-MS method was applied to a human prostate cancer study and was shown to discriminate between treatment regimens and to identify amino acids responsible for the statistical separation between healthy controls and prostate cancer patients on active surveillance.